Enzychem Lifesciences Corporation (183490) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Enzychem Lifesciences Corporation (183490:KRX), powered by AI.
- Current Price
- ₩990
- P/E Ratio
- -3.7
- Market Cap
- 83.8B
- Sector
- Healthcare
What is the Enzychem Lifesciences Corporation stock price forecast?
Enzychem Lifesciences Corporation is currently trading at ₩990. View real-time AI analysis on Alpha Lenz.
What is Enzychem Lifesciences Corporation insider trading activity?
View the latest insider trading data for Enzychem Lifesciences Corporation on Alpha Lenz.
What is Enzychem Lifesciences Corporation's P/E ratio?
Enzychem Lifesciences Corporation's P/E ratio is -3.7.
Enzychem Lifesciences Corporation
KRX · 183490“Enzychem Lifesciences Corporation trades at a P/E of -3.7 (undervalued) with modest ROE of -12.5%. 3Y revenue CAGR of 49.9% highlights clear growth momentum.”
Ask for details →Company Overview
Enzychem Lifesciences Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs. The company primarily concentrates on areas such as oncology, inflammatory diseases, and infectious diseases. Leveraging its proprietary compound, EC-18, derived from Sitr-1, a natural substance found in beef tallow, Enzychem works to harness anti-inflammatory and anti-fibrotic properties. Enzychem Lifesciences Corporation's EC-18 is under exploration for its potential in treating conditions like chemotherapy-induced neutropenia and radiation therapy side effects. This positions the company at the nexus of vital health sectors, addressing critical gaps where few effective treatments exist. Headquartered in South Korea, Enzychem plays a significant role in advancing pharmaceutical frontiers, contributing to global health solutions, and navigating complex clinical trials that aim to bring transformative treatments to the healthcare industry. The company's dedication to innovative research is integral to its market standing, impacting the drug development landscape by potentially improving patient outcomes and enhancing quality of life for those affected by severe medical conditions.
Company Statistics
FY 2024Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Enzychem Lifesciences Corporation trades at a P/E of -3.7 (undervalued) with modest ROE of -12.5%. 3Y revenue CAGR of 49.9% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
Enzychem Lifesciences Corporation (ticker: 183490) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 127 employees. Market cap is $83.8B.
The current price is ₩990 with a P/E ratio of -3.67x and P/B of 0.51x.
ROE is -12.49% and operating margin is -25.77%. Annual revenue is $77.4B.